


# Could FASENRA® be an option for your patients?



## Eric

Accountant | Age 44

Choose FASENRA® for patients like Eric

### History:

- Recently diagnosed with severe asthma.
- Recently had a second exacerbation resulting in an ER visit.

### Examination:<sup>1,2</sup>

- Pre-bronchodilator FEV<sub>1</sub>: 1.9 L (64%)
- Blood eosinophils: 320 cells/ $\mu$ L
- Total IgE: 340 IU/mL
- Skin prick test: Positive for perennial aeroallergens
- ACQ-6 score: 2.8

### Current Treatments:

- High-dose ICS + LABA

FASENRA® (benralizumab injection) is indicated as an add-on maintenance treatment of adult patients with severe eosinophilic asthma.<sup>1</sup>

Fictitious patient. May not be representative of all cases.

ACQ-6: Asthma Control Questionnaire, six-question version; ER: emergency room; FEV<sub>1</sub>: forced expiratory volume in 1 second; ICS: inhaled corticosteroid; IgE: immunoglobulin E; LABA: long-acting beta<sub>2</sub>-agonist.

Consult the [Product Monograph](#) for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling **1-800-668-6000**.

**References:** 1. FASENRA® Product Monograph, AstraZeneca Canada Inc. 2. Bleecker ER, FitzGerald JM, Chanez P, *et al.* Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting  $\beta_2$ -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*. 2016;388(10056):2115–2127 (incl. supplement).